Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy

Click to increase image sizeClick to decrease image size

Disclosure statement

	Rory Michael Shallis: No relevant financial relationship(s) to disclose
	Maximilian Stahl: No relevant financial relationship(s) to disclose
	Wei Wei: No relevant financial relationship(s) to disclose
	Pau Montesinos: Daiichi Sankyo: Consultancy and Speakers Bureau; Novartis: Research Funding and Speakers Bureau
	Etienne Lengline: No relevant financial relationship(s) to disclose
	Judith Neukirchen: No relevant financial relationship(s) to disclose
	Vijaya R. Bhatt: Consulting fees: CSL Behring, Agios, Abbvie, Partner therapeutics and Incyte; Research funding: Jazz, Incyte, Tolero Pharmaceuticals, Inc, and National Marrow Donor Program.
	Mikkael A. Sekeres: No relevant financial relationship(s) to disclose
	Amir T. Fathi: Consulting/advisory board – Celgene, Takeda, Abbvie, Forty seven, NewLink, Trovagene, Pfizer, Daiichi Sankyo, Astellas, Amphivena; Clinical trial funding – Celgene and Agios
	Heiko Konig: No relevant financial relationship(s) to disclose
	Selina Luger: No relevant financial relationship(s) to disclose
	Irum Khan: Teva: Speakers Bureau
	Gail J. Roboz: AbbVie: Consultancy; Aphivena Therapeutics: Consultancy; Argenx: Consultancy; Astex Pharmaceuticals: Consultancy; Bayer: Consultancy; Celgene Corporation: Consultancy; Celltrion: Consultancy; Daiichi Sankyo: Consultancy; Bayer: Consultancy; Eisai: Consultancy; Janssen Pharmaceuticals: Consultancy; Jazz Pharmaceuticals: Consultancy; Novartis: Consultancy; Orsenix: Consultancy; Otsuka: Consultancy; Pfizer: Consultancy; Roche/Genentech: Consultancy; Sandoz: Consultancy; Cellectis: Research Fundin; Orsenix: Consultancy
	Thomas Cluzeau: Celgene: Consultancy, Membership on an entity’s Board of Directors or advisory committees and Speakers Bureau; Menarini: Consultancy; Jazz Pharma: Consultancy, Membership on an entity’s Board of Directors or advisory committees and Speakers Bureau; Amgen: Membership on an entity’s Board of Directors or advisory committees and Speakers Bureau; AbbVie: Membership on an entity’s Board of Directors or advisory committees and Speakers Bureau; Sanofi: Speakers Bureau; Pfizer: Speakers Bureau
	David Martínez-Cuadron: No relevant financial relationship(s) to disclose
	Emmanuel Raffoux: No relevant financial relationship(s) to disclose
	Ulrich Germing: Celgene: Honoraria, Research Funding and Consultancy; Novartis: Honoraria and Research Funding; Janssen: Honoraria
	Jayadev Manikkam Umakanthan: No relevant financial relationship(s) to disclose
	Sudipto Mukherjee: Aplastic Anemia & MDS International Foundation in Joint Partnership with Cleveland Clinic Taussig Cancer Institute: Honoraria; BioPharm Communications: Consultancy; Bristol Myers Squib: Honoraria and Speakers Bureau; LEK Consulting: Consultancy and Honoraria; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees and Research Funding; Pfizer: Honoraria; Projects in Knowledge: Honoraria; Takeda: Membership on an entity’s Board of Directors or advisory committees
	Andrew M. Brunner: Takeda: Research Funding; Celgene: Consultancy and Research Funding; Novartis: Research Funding
	Adam M. Miller: No relevant financial relationship(s) to disclose
	Christine M. McMahon: No relevant financial relationship(s) to disclose
	Ellen K. Ritchie: Incyte: Consultancy and Speakers Bureau; Celgene: Consultancy, Other: Travel, Accommodations, Expenses and Speakers Bureau; Pfizer: Consultancy and Research Funding; Novartis: Consultancy, Other: Travel, Accommodations, Expenses, Research Funding and Speakers Bureau; ARIAD Pharmaceuticals: Speakers Bureau; Astellas Pharma: Research Funding; BristolMyers Squibb: Research Funding; NS Pharma: Research Funding
	Rebeca Rodríguez Veiga: No relevant financial relationship(s) to disclose
	Raphael Itzykson: No relevant financial relationship(s) to disclose
	Blanca Boluda: No relevant financial relationship(s) to disclose
	Florence Rabian: No relevant financial relationship(s) to disclose
	Mar Tormo: No relevant financial relationship(s) to disclose
	Evelyn Gloria Acuna Cruz: No relevant financial relationship(s) to disclose
	Emma Rabinovich: No relevant financial relationship(s) to disclose
	Brendan Yoo: No relevant financial relationship(s) to disclose
	Isabel Cano: No relevant financial relationship(s) to disclose
	Nikolai A. Podoltsev: Agios Pharmaceuticals: Consultancy and Honoraria; Astellas Pharma: Research Funding; Blueprint Medicines: Consultancy and Honoraria; Incyte: Consultancy and Honoraria; Novartis: Consultancy and Honoraria; Boehringer Ingelheim: Research Funding; Daiichi Snakyo: Research Funding; Sunesis Pharmaceuticals: Research Funding; Celator: Research Funding; Pfizer: Research Funding, Consultancy and Honoraria; Astex Pharmaceuticals: Research Funding; Celgene: Research Funding, Consultancy and Honoraria; Genentech: Research Funding; AI Therapeutics: Research Funding; Samus Therapeutics: Research Funding; Arog Pharmaceuticals: Research Funding; Kartos Therapeutics: Research Funding
	Jan Philipp Bewersdorf: No relevant financial relationship(s) to disclose
	Steven D. Gore: No relevant financial relationship(s) to disclose; Celgene: Consultancy and Research Funding
	Amer M. Zeidan: A.M.Z. received research funding from Celgene, Acceleron, Abbvie, Otsuka, Pfizer, Medimmune/AstraZeneca, Boehringer-Ingelheim, Trovagene, Incyte, Takeda, Novartis, Aprea, Astex, and ADC Therapeutics. A.M.Z had a consultancy with and received honoraria from AbbVie, Otsuka, Pfizer, Celgene, Jazz, Incyte, Agios, Boehringer-Ingelheim, Novartis, Acceleron, Astellas, Daiichi Sankyo, Cardinal Health, Seattle Genetics, BeyondSpring, Trovagene, Takeda, Ionis, and Epizyme. A.M.Z received travel support for meetings from Pfizer, Novartis, and Trovagene. None of these relationships were related to the development of this manuscript.

Acknowledgements

Amer Zeidan is a Leukemia and Lymphoma Society Scholar in Clinical Research and is also supported by a NCI’s Cancer Clinical Investigator Team Leadership Award (CCITLA). Research reported in this publication was in part supported by the National Cancer Institute of the National Institutes of Health under Award Number P30 CA016359. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. We would like to acknowledge all the patients, and the Frederick A. DeLuca Foundation for supporting the statistical analyses.

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

Maximilian Stahl received funding from the MSKCC Clinical Scholars T32 Program under award number 2T32 CA009512-31.